Endometrial cancer drug trial halted early: letrozole shows no clear benefit
NCT ID NCT05454358
First seen Jan 11, 2026 · Last updated Jun 17, 2026 · Updated 25 times
Summary
This study aimed to see if taking letrozole (a hormone therapy) after standard treatment could help prevent endometrial cancer from coming back in patients with a non-specific molecular profile. The trial was stopped early after enrolling only 12 participants, so no firm conclusions can be drawn. The approach was to compare letrozole maintenance versus simple observation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Obstetrics and Gynecology Hospital of Fudan University
Shanghai, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.